Breaking News Instant updates and real-time market news.

SNY

Sanofi

$49.01

-0.61 (-1.23%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$28.00

-0.015 (-0.05%)

04:55
10/25/17
10/25
04:55
10/25/17
04:55

Worldwide Business Research to hold a summit

BioNetwork Partnering Summit is being held in Laguna Nigel, CA on October 23-25.

SNY

Sanofi

$49.01

-0.61 (-1.23%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$28.00

-0.015 (-0.05%)

UNH

UnitedHealth

$208.15

1.14 (0.55%)

NVS

Novartis

$83.13

-2.78 (-3.24%)

HZNP

Horizon Pharma

$13.75

-0.11 (-0.79%)

ABBV

AbbVie

$91.69

-2.82 (-2.98%)

BAYRY

Bayer

$34.31

-0.205 (-0.59%)

MRK

Merck

$63.11

-0.29 (-0.46%)

RDHL

RedHill Biopharma

$9.05

-0.06 (-0.66%)

NBRV

Nabriva Therapeutics

$5.90

-0.17 (-2.80%)

PFE

Pfizer

$36.27

-0.13 (-0.36%)

TEVA

Teva

$14.28

-0.26 (-1.79%)

GILD

Gilead

$80.10

-0.07 (-0.09%)

ALXN

Alexion

$136.66

1.46 (1.08%)

GSK

GlaxoSmithKline

$40.48

-0.14 (-0.34%)

REGN

Regeneron

$426.51

-6.25 (-1.44%)

CELG

Celgene

$120.34

-2.03 (-1.66%)

LLY

Eli Lilly

$85.17

-2.01 (-2.31%)

AMGN

Amgen

$180.37

-0.16 (-0.09%)

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 27

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 08

    Nov

  • 09

    Nov

  • 13

    Nov

  • 16

    Nov

  • 16

    Nov

  • 30

    Nov

  • 30

    Nov

  • 02

    Dec

  • 04

    Dec

  • 02

    Feb

  • 03

    Feb

  • 12

    Feb

  • 30

    Apr

  • 17

    May

  • 28

    May

SNY Sanofi
$49.01

-0.61 (-1.23%)

10/24/17
PIPR
10/24/17
NO CHANGE
Target $107
PIPR
Overweight
Eli Lilly Humalog fears overblown, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss attributes Eli Lilly's (LLY) post-earnings decline to further anxiety around price competition in the U.S. diabetes segment after the company said on its earnings call that it will not challenge Sanofi's (SNY) biosimilar for Humalog. However, he sees these concerns as substantially overdone, pointing to the 39% year-over-year growth reported in Q3 for the diabetes franchise, and view today's pullback as a clear buying opportunity. Purkiss keeps an Overweight rating on Eli Lilly and raised his price target on the stock to $107 from $105.
09/11/17
FBCO
09/11/17
NO CHANGE
Target $485
FBCO
Outperform
Regeneron, Sanofi asthma trial 'statistically significant,' says Credit Suisse
Credit Suisse analyst Alethia Young notes that Regeneron (REGN)/Sanofi (SNY) released top-line asthma results, and the overall trial was "statistically significant." Specifically, the trial hit in the overall population, but it is unclear if the trial was statistically significant in the low eosinophil level patients alone, she notes. The analyst reiterates an Outperform rating and $485 price target on Regeneron's shares.
10/11/17
BARD
10/11/17
NO CHANGE
Target $69
BARD
Outperform
AnaptysBio price target raised to $69 from $36 at Baird
Baird analyst Neena Bitritto-Garg raised her price target on AnaptysBio (ANAB) to $69 from $36 following positive proof-of-concept data for its anti-IL-33 antibody, adding that its scores look more impressive than Sanofi (SNY) and Regeneron's (REGN) initial data for atopic dermatitis for Dupixent. The analyst raised her price target to reflect the strong validation of its mechanism and Bitritto-Garg reiterated her Outperform rating on AnaptysBio shares.
10/05/17
PIPR
10/05/17
NO CHANGE
PIPR
Overweight
Regeneron, Sanofi overhang removed by court ruling, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that the U.S. Court of Appeals ruled in favor of Regeneron (REGN) and Sanofi (SNY) and vacated an injunction granted to Amgen (AMGN) to compel its competitors to pull Praluent from the market. While "this battle is far from over" and Raymond expects a new trial will be the next step, he also believes the ruling remove a significant marketing overhang that had hamstrung Regeneron and Sanofi sales reps. The analyst keeps an Overweight rating on Regeneron shares, which are currently halted with news pending.
TKPYY Takeda Pharmaceutical Co. Ltd.
$28.00

-0.015 (-0.05%)

10/03/17
JMPS
10/03/17
NO CHANGE
Target $25
JMPS
Outperform
Myovant Phase 3 results further de-risk ongoing trials, says JMP Securities
After Myovant Sciences (MYOV) and partner Takeda (TKPYY) announced a Japanese study evaluating the efficacy and safety of relugolix to treat uterine fibroids met its primary endpoint, JMP Securities analyst Jason Butler said the results represent a "best case outcome" and have a clear positive read through to ongoing international Phase 3 trials in uterine fibroids and endometriosis. The analyst, who increased his view of the probability of success in UF and EM, raised his price target on Myovant shares to $25 from $23 and keeps an Outperform rating on the stock.
01/17/17
PIPR
01/17/17
NO CHANGE
Target $15
PIPR
Overweight
Array BioPharma strength likely aided by M&A speculation, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff noted that Array BioPharma (ARRY) shares hit a 52-week high during Friday's trading, which he attributes to M&A speculation following Ariad's (ARIA) agreement to be acquired by Takeda (TKPYY). Tenthoff, who sees several business development opportunities for Array, reiterates his Overweight rating and $15 price target on the shares.
02/06/17
02/06/17
UPGRADE
Target $67

Outperform
PRA Health upgraded to Outperform at Credit Suisse
As previously reported, Credit Suisse analyst Erin Wilson Wright upgraded PRA Health (PRAH) to Outperform from Neutral on greater enthusiasm for the company's recent partnership with Takeda (TKPYY), an incrementally more positive outlook for the broader functional outsourcing market, and relatively healthy CRO industry fundamentals. The analyst also raised her price target on PRA Health's shares to $67 from $50.
01/31/17
01/31/17
NO CHANGE

Exelixis down with licensing deal seen as impacting takeover potential
Shares of Exelixis (EXEL) are moving lower after the company last night announced a licensing agreement for the commercialization and further clinical development in Japan of cabozantinib, its oncology medicine, with Takeda Pharmaceutical (TKPYY). Deutsche Bank analyst Andrew Peters said earlier today that while Exelixis' licensing agreement is "clearly encouraging" and highlights the value of cabozantinib, the news could impact "near-term expectations regarding strategic activity, as Japanese rights would be similarly valuable to maintain." Exelixis is down 4%, or 66c, to $17.62 in afternoon trading, a sign that the deal with Takeda could be dampening investor expectations of a buyout in the near-term. The company maintaining the U.S. rights is key, Peters told investors in a research note, adding that the U.S. is core to the valuation and the company's strategic positioning. The analyst has a Buy rating on Exelixis with a $20 price target.
UNH UnitedHealth
$208.15

1.14 (0.55%)

10/18/17
MSCO
10/18/17
NO CHANGE
Target $235
MSCO
Overweight
Morgan Stanley says executive order could be upside opportunity for UnitedHealth
Morgan Stanley analyst Zack Sopcak noted that UnitedHealth said it expects 2018 EPS growth to be within its long-term range of 13%-16%. However, he believes the company tends to be conservative with its initial guidance, which may be even more true now given its new CEO. Also, management noted on the earnings call that the company has previously successfully sold both short-term plans and association health plans, and Sopcak said the recent Trump executive order regarding CSR subsidies could provide an upside opportunity for UnitedHealth. The analyst keeps an Overweight rating on UnitedHealth shares and raised his price target on the stock to $235 from $215.
10/18/17
ADAM
10/18/17
NO CHANGE
Target $42
ADAM
Buy
Teledoc well positioned with telehealth still in early innings, says Canaccord
Canaccord analyst Richard Close believes telehealth remains in the early innings and he said he remains an aggressive buyer of Teledoc (TDOC) as its market position continues to strengthen. He is bullish on the company's growth prospects and competitive market position and said the selling season is shaping up well with UnitedHealth (UNH) providing the greatest near-term opportunity. Close reiterated his Buy rating and $42 price target on Teledoc shares.
10/18/17
OPCO
10/18/17
NO CHANGE
Target $215
OPCO
Outperform
UnitedHealth price target raised to $215 from $205 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for UnitedHealth to $215 from $205 following quarterly results and "robust outlook." The analyst reiterates an Outperform rating on the shares.
10/19/17
BERN
10/19/17
NO CHANGE
Target $219
BERN
Outperform
UnitedHealth price target raised to $219 from $210 at Bernstein
Bernstein analyst Lance Wilkes raised his price target for UnitedHealth to $219 from $210 following a "solid quarter" with EPS beat and raise. The analyst reiterates an Outperform rating on the shares.
NVS Novartis
$83.13

-2.78 (-3.24%)

10/25/17
LEHM
10/25/17
DOWNGRADE
LEHM
Underweight
Novartis downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Emmanuel Papadakis downgraded Novartis to Underweight and cut his price target for the shares to CHF 75 from CHF 80. Following the Q3 results, the analyst believes Entresto estimates remain too high and that competitive pressure increasing for Cosentyx. He sees a lack of catalysts in the near-term beyond RTH258.
10/16/17
JEFF
10/16/17
NO CHANGE
Target $115
JEFF
Buy
Jefferies ups price target on top global pick AbbVie to $115
Jefferies analyst Jeffrey Holford keeps AbbVie (ABBV) as his top global Pharmaceuticals pick for October, followed by Roche (RHHBY), Novartis (NVS), Bayer (BAYRY), Johnson & Johnson (JNJ), Eli Lilly (LLY) and GlaxoSmithKline (GSK). The analyst raised his price target for AbbVie shares to $115 from $107 and keeps a Buy rating on the name. Among his other target changes include bumping Eli Lilly's to $100 from $96.
10/20/17
10/20/17
DOWNGRADE
Target $0.9

Hold
Durect downgraded to Hold on 'major disappointment' of Posimir failure at Stifel
As previously reported, Stifel analyst Adam Walsh downgraded Durect (DRRX) to Hold from Buy, calling the fact that the company's Phase 3 Posimir trial in post-surgical pain did not meet its primary efficacy endpoint a "major disappointment." He has removed all Posimir revenue from his model and expects Novartis' (NVS) Sandoz will end the Posimir partnership. Walsh lowered his price target to 90c from $3.00 on Durect shares, which are down 55% to 87c in pre-market trading.
10/09/17
MAXM
10/09/17
NO CHANGE
Target $56
MAXM
Buy
Juno price target raised to $56 on higher JCAR017 price assumptions at Maxim
Maxim analyst Jason McCarthy has increased his assumptions for pricing of Juno Therapeutics' (JUNO) JCAR017 to $450K from $300K in the U.S. and to $375K from $200K in the EU, leading him to also raise his price target on the stock to $56 from $34. He believes CAR-T remains "a three horse race," adding that while Novartis (NVS) and Gilead's (GILD) Kite are ahead, "Juno is coming up from behind." McCarthy maintains his Buy rating on Juno shares.
HZNP Horizon Pharma
$13.75

-0.11 (-0.79%)

09/27/17
JMPS
09/27/17
NO CHANGE
Target $22
JMPS
Outperform
Horizon Pharma has other patents to protect Ravicti, says JMP Securities
After Lupin won its challenge to Horizon Pharma's '559 patent for Ravicti, JMP Securities analyst Donald Ellis noted that Horizon will appeal the IPR decision, which could take 12-18 months. Also, Ravicti has the recently issued '197 patent, which is unaffected by the '559 decision and extends until 2030, he tells investors. Ellis reiterates his Outperform rating and $22 price target on Horizon Pharma shares, which slid about 2% to $11.95 yesterday following the USPTO ruling.
09/27/17
CANT
09/27/17
NO CHANGE
Target $17
CANT
Overweight
Horizon loss of exclusivity not foregone conclusion, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen does not think it is a forgone conclusion that Horizon Pharma will lose brand exclusivity for Ravicti after the United States Patent and Trademark Office ruled in favor of Lupin regarding the inter partes review of the '559 patent. Ravicti has orphan drug exclusivity that extends to 2020, and multiple other patents protecting the drug, Chen tells investors in a research note. There are no IPRs filed on the '197 patent, which is new, the analyst points out. She still likes shares of Horizon with an Overweight rating and $17 price target.
10/05/17
JEFF
10/05/17
NO CHANGE
Target $16
JEFF
Buy
Horizon's largest potential drug not included in Street models, says Jefferies
Following the "strong" recent Phase 2 results, clinicians believe Horizon Pharma's teprotumumab could become the thyroid eye disease therapy of choice, Jefferies analyst David Steinberg tells investors in a research note titled "'Tepro' Could Be HZNP's Largest Product - but the Street Doesn't Value It." The drug, however, is largely excluded from Street models, the analyst adds. He believes that teprotumumab, if approved, could conservatively research peak sales of $500M, implying 23% upside to the current valuation. Further, if the drug proves to be truly disease-modifying, peak revenue could reach $1.5B, implying 68% upside, Steinberg writes. He feels current therapies for TED are "very limited" and that the drug development pipeline is "lackluster." Steinberg has a Buy rating on Horizon Pharma with a $16 price target.
09/28/17
GSCO
09/28/17
INITIATION
GSCO
Buy
Horizon Pharma initiated with a Buy at Goldman Sachs
Goldman analyst Dana Flanders initiated Horizon Pharma with a Buy and a $16 price target. Flanders said shares have underperformed due to the company's high level of M&A activity but expects strong cash flow generation and capital allocation towards orphan and specialty assets to drive long-term topline growth and margins.
ABBV AbbVie
$91.69

-2.82 (-2.98%)

10/18/17
GSCO
10/18/17
NO CHANGE
GSCO
Goldman says to swap Celgene for AbbVie
Goldman analyst Jami Rubin thinks AbbVie's (ABBV) pipeline is significantly undervalued and expects it to grow to $25B in 2028 on a risk adjusted basis from $3B in 2017 driven by diverse assets, which essentially offsets losses from Humira. Rubi said Celgene (CELG) faces a cliff when generic competition comes into Revlimid and said the pipeline is not large enough to offset the erosion. The analyst recommends swapping out of Sell rated Celgene and into Buy rated AbbVie.
10/16/17
JEFF
10/16/17
DOWNGRADE
Target $71
JEFF
Hold
Bristol-Myers downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Bristol-Myers Squibb (BMY) to Hold saying the shares, following the recent rally, have "significant downside risk" should lung cancer trial CheckMate-227 fail. Further, other consolidation targets, such as AbbVie (ABBV), may have become more attractive, potentially threatening Bristol's downside protection, Holford tells investors in a research note. He attributes the recent rise in Bristol shares to takeover speculation and favorable flows into Biopharma names. Holford still sees "significant potential upside" if CM-227 reads out positively, but he only assigns a 50% probability to this. He lowered his price target for Bristol-Myers shares to $71 from $72. The stock closed Friday down 6c to $65.29.
10/13/17
LEHM
10/13/17
NO CHANGE
LEHM
Barclays cautious on Merck and Regeneron into Q3 results
In a research note previewing the Q3 earnings reports for U.S. Biopharmaceuticals, Barclays analyst Geoff Meacham says he's positive on positive on Amgen (AMGN) and Alexion Pharmaceuticals (ALXN), cautious on Merck (MRK), and bearish on Regeneron (REGN). The analyst made a host of price target changes, including raising Amgen's target to $190 from $180, AbbVie's (ABBV) target to $90 from $68 and Bristol-Myers' target to $65 from $58.
BAYRY Bayer
$34.31

-0.205 (-0.59%)

10/16/17
RHCO
10/16/17
NO CHANGE
Target $35
RHCO
Buy
Cabo result better positions Exelixis as acquisition target, says SunTrust
SunTrust analyst Peter Lawson raised his price target on Exelixis (EXEL) to $35 from $33 and maintained his Buy rating, saying the latest CELESTIAL trial cabozantinib positions the treatment well against its main competitor - Bayer's (BAYRY) Regorafenib. Lawson adds that the trial result validates the expansion of cabozantinib beyond kidney cancer and better positions Exelixis as a potentially attractive M&A target.
10/03/17
RHCO
10/03/17
NO CHANGE
RHCO
TG Therapeutics has positive read through from Bayer approval, says SunTrust
SunTrust analyst Yatin Suneja believes that the FDA's decision to grant accelerated approval to Bayer's (BAYRY) Aliqopa, a PI3K-delta inhibitor, as a treatment for Relapsed/Refractory Follicular Lymphoma, bodes well for TG Therapeutics' (TGTX) own PI3K-delta inhibitor, TGR-120. The analyst says that the lack of a black box warning on Bayer's Aliqopa shows that not all PI3K-delta inhibitors have the safety issues that have been attributed to them in the past. Suneja says that "Aliqopa's approval reflects positively on TGR-1202, which offers best-in-class safety , and provides clarity on TGR-1202's regulatory pathway in" lymphoma The analyst says that investors are "overlooking" its potential in " lymphoma, and keeps a Buy rating on the shares.
10/17/17
NEED
10/17/17
NO CHANGE
Target $33
NEED
Buy
Exelixis price target raised to $33 from $30 at Needham
Needham analyst Chad Messer raised his price target on Exelixis (EXEL) to $33, noting the latest trial data for advanced renal cell carcinoma treatment, Cabozantinib, positions it for near and long term growth. Messer says the results may be sufficient to allay competitive concerns from the recently approved Bayer (BAYRY) Stivarga, as cabozantinib offers a potentially more attractive efficacy profile.
MRK Merck
$63.11

-0.29 (-0.46%)

10/18/17
10/18/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at Citi with analyst Andrew Baum saying while Merck's non-Keytruda business continues to erode, the market is undervaluing both the ultimate patient derived xenograft market size and Merck's likely market share with Keytruda. 2. GoPro (GPRO) upgraded to Buy from Neutral at Longbow with analyst Joe Wittine noting that the stock's valuation has returned to early 2017 levels, which he views as "misguided" given the execution improvement made since that time. 3. Omnicom (OMC) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Tom Eagan saying Omnicom's North American growth for the third quarter was up 2.1%, a turnaround from the first half of 2017 deceleration. 4. Magna (MGA) upgraded to Buy from Underperform at BofA/Merrill with analyst John Murphy upgrading Magna two notches and saying the company has the expertise in numerous components and architectures of the vehicle that provide a unique competitive advantage in the evolution of the automotive industry towards technological advancement. 5. Grainger (GWW) upgraded to Outperform from Perform at Oppenheimer with analyst Christopher Glynn citing the company's third quarter results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/18/17
SBSH
10/18/17
UPGRADE
Target $72
SBSH
Buy
Merck upgraded to Buy from Neutral at Citi
Citi analyst Andrew Baum upgraded Merck (MRK) to Buy and raised his price target for the shares to $72 from $65. The healthcare giant closed yesterday down 12c to $63.22. While Merck's non-Keytruda business continues to erode, the market is undervaluing both the ultimate patient derived xenograft market size and Merck's likely market share with Keytruda, Baum tells investors in a research note. The analyst revised his initial PDx market estimates of $35bn to at least $50bn and increased his 2025 Keytruda forecasts from $9B to$15B. The analyst prefers Eli Lilly (LLY), Bristol-Myers (BMY) and Merck among the U.S. pharmaceutical majors. He also downgraded Roche (RHHBY) this morning to Neutral.
10/16/17
BTIG
10/16/17
NO CHANGE
Target $27
BTIG
Buy
KalVista price target raised to $27 after Merck pact at BTIG
BTIG analyst Robert Hazlett said KalVista's (KALV) collaboration with Merck (MRK) underscores the material potential of the plasma kallikrein approach in diabetic macular edema. He also thinks that the larger company's agreement to take a stake signals confidence in KalVista's approach to hereditary angioedema treatment. He raised his price target KalVista to $27 from $18 following the collaboration agreement announcement and keeps a Buy rating on the shares, which are up 5% in pre-market trading.
10/19/17
MAXM
10/19/17
NO CHANGE
Target $5
MAXM
Buy
OncoSec data continues to build for Keytruda combination, says Maxim
Maxim analyst Jason McCarthy noted that OncoSec (ONCS) presented "positive" data demonstrating that at 6 months the combination of the company's TAVO with Merck's (MRK) Keytruda in melanoma patients that are non-responders to checkpoint therapy induced a best overall response rate of 50%. The Phase 2b registration study with Merck is now underway and good results would be a "significant incentive" for Merck to support the combination, said McCarthy, who keeps a Buy rating and $5 price target on OncoSec shares.
RDHL RedHill Biopharma
$9.05

-0.06 (-0.66%)

10/06/17
GHSC
10/06/17
INITIATION
Target $19
GHSC
Buy
RedHill Biopharma initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated RedHill Biopharma with a Buy and $19 price target.
NBRV Nabriva Therapeutics
$5.90

-0.17 (-2.80%)

09/18/17
RHCO
09/18/17
NO CHANGE
Target $24
RHCO
Buy
Nabriva Therapeutics price target raised to $24 from $20 at SunTrust
SunTrust analyst Edward Nash raised his price target for Nabriva Therapeutics to $24 saying this morning's data verify lefamulin as a novel antibiotic for community acquired bacterial pneumonia. The analyst keeps a Buy rating on the shares.
09/18/17
WEDB
09/18/17
NO CHANGE
Target $21
WEDB
Outperform
Wedbush calls Nabriva data 'giant leap,' ups target to $21
Wedbush analyst Robert Driscoll raised his price target for Nabriva Therapeutics to $21 from $13 after the company's Phase 3 study for lefamulin against pneumonia met the primary endpoint. The analyst calls the data a "giant leap" for lefamulin. He has an Outperform rating on Nabriva. The shares in midday trading are up 37% to $9.43.
08/25/17
RHCO
08/25/17
INITIATION
RHCO
Buy
Nabriva Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Edward Nash started coverage of Nabriva Therapeutics with a $20 price target and a Buy rating. The analyst says that the company's antibiotic, Lefamulin, is "a late stage asset targeting a sizeable market." He says that the drug targets a U.S. incidence rate of more than 5M and he estimates that it can achieve worldwide sales of over $700M.
09/18/17
LEER
09/18/17
NO CHANGE
Target $22
LEER
Outperform
Nabriva Therapeutics price target raised to $22 from $20 at Leerink
PFE Pfizer
$36.27

-0.13 (-0.36%)

10/12/17
DADA
10/12/17
NO CHANGE
Target $79
DADA
Buy
Pfizer announcement creates M&A opportunity for Prestige Brands,says DA Davidson
DA Davidson analyst Linda Bolton Weiser says Pfizer's (PFE) announcement that is is reviewing strategic alternatives for its $3.4B OTC drug business could create M&A opportunity down the road for Prestige Brands (PBH). If sold, the price tag could be over $10B, clearly too big for Prestige Brands, but the buyer could later sell some or all of the small brands, the analyst contended. With Prestige Brands continuing to de-lever its balance sheet and approaching the one year anniversary in January of its last deal, Weiser believes the company could within months announce an accretive acquisition. She reiterates a Buy rating and $79 price target on Prestige Brands shares.
10/11/17
DBAB
10/11/17
NO CHANGE
Target $38
DBAB
Buy
Pfizer sale of consumer unit most likely option, says Deutsche Bank
Deutsche Bank analyst Gregg Gilbert believes a sale of Pfizer's Consumer Healthcare unit is the most likely outcome of the company's strategic review process. The analyst says he wouldn't be surprised if Pfizer has already received indications of interest in the business. A sale of the unit could be 3%-4% accretive depending on the price and assuming the company uses the proceeds to repurchase shares in order to offset dilution, Gilbert tells investors in a research note. He likes that management continues to explore strategic alternatives to increase shareholder value and keeps a Buy rating on Pfizer with a $38 price target.
09/29/17
MSCO
09/29/17
NO CHANGE
Target $86
MSCO
Equal Weight
Morgan Stanley calls Verzenio liver toxicity warning a 'minor' negative surprise
Morgan Stanley analyst David Risinger said he was expecting warnings on diarrhea and blood clot risks for Eli Lilly's (LLY) Verzenio, but not liver toxicity, calling that part of the approval a "minor" negative surprise. However, the approval came ahead of the Q1 timeline management had provided, he added. Bloomberg reports that Verzenio will cost $10,948 per month, which is in-line with the current monthly costs for Pfizer's (PFE) Ibrance and Novartis' (NVS) Kisqali, Risinger noted. He keeps an Equal Weight rating and $86 price target on Eli Lilly shares.
09/20/17
09/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger saying he believes investors underappreciate the global prospects for breast cancer drug Ibrance, which he expects to maintain its first-to-market advantage. 2. Progressive (PGR) upgraded to Neutral from Underperform at Credit Suisse with analyst Ryan Tunis citing the announcement of much lower than expected Harvey losses of approximately $230M versus his estimate of $550M. 3. American Airlines (AAL) and Southwest (LUV) were upgraded to Outperform from Market Perform at Raymond James. 4. Post Holdings (POST) upgraded to Outperform from Market Perform at BMO Capital with analyst Kenneth Zaslow saying he expects the company to be boosted by egg price increases. 5. Nordson (NDSN) upgraded to Buy from Neutral at Longbow with analyst Christopher Dankert saying ATS growth concerns are overblown and views valuation as attractive. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TEVA Teva
$14.28

-0.26 (-1.79%)

10/04/17
JPMS
10/04/17
NO CHANGE
JPMS
Overweight
JPMorgan says generic Copaxone approval 'meaninful positive' for Mylan
Mylan's (MYL) generic Copaxone approval, 9-12 months ahead of investor expectations, represents a "meaningful positive" for the story and will "substantially derisk/support" upside to 2017 and 2018 estimates, JPMorgan analyst Chris Schott tells investors in a research note. The analyst reiterates an Overweight rating on the shares. For Teva (TEVA), the approval puts further pressure on the company's "already challenged" near-term earnings profile and delevering efforts, Schott writes. The analyst keeps a Neutral rating on the shares. The analyst believes the earlier than expected approval for Mylan represents a setback for Momenta Pharmaceuticals' (MNTA) generic Copaxone opportunity. Schott had assumed the company's Glatopa would be the first generic version of Copaxone 40mg to enter the market, but he notes the product has been delayed due to manufacturing issues at a Pfizer (PFE) plant handling fill/ for the drug. The analyst, however, continues to see a "large and fairly durable" generic opportunity for Glatopa. He keeps an Overweight rating on Momenta shares, which are down 27% in premarket trading to $12.75. Mylan is up 17% to $38.20 while Teva is down 15% to $15.95.
10/04/17
BTIG
10/04/17
NO CHANGE
BTIG
Mylan generic Copaxone sales could reach $450M in first year, says BTIG
BTIG analyst Timothy Chiang estimates that Mylan (MYL) could obtain up to $450M of sales from its generic version of Teva's (TEVA) Copaxone in the first year in which it is marketed. The analyst believes that the approval "validates" the company's status as a "premier" generic drugmaker and shows that one can never assume that it will lose a battle over generic drug rights. The analyst raised his price target on the shares to $45 from $42 and keeps a Buy rating on the stock.
10/16/17
WELS
10/16/17
NO CHANGE
WELS
Outperform
Court ruling looks 'clearly negative' for Allergan, says Wells Fargo
Wells Fargo analyst David Maris says a federal judge ruling today that Allergan's (AGN) Restasis patents are invalid "appears clearly negative" for the company. Due to the magnitude of the potential damages involved, however, an at-risk generic launch is unlikely, Maris tells investors in an intraday research note. As such, the analyst continues to believe the earliest that a generic version of Restasis may enter the market is sometime in 2019. Maris keeps an Outperform rating on Allergan. He adds that today's court ruling is incrementally positive for generic Restasis filers, if approved, including Teva (TEVA), Mylan ( MYL) and Akorn (AKRN).
10/13/17
WELS
10/13/17
NO CHANGE
Target $276
WELS
Outperform
Allergan settlement leaves three Restasis challengers, say Wells Fargo
Wells Fargo analyst David Maris says three Restasis generic challengers remain after Allergan (AGN) reached a settlement with InnoPharma. The settlement, which allows InnoPharma to launch a generic Restasis in the U.S. beginning February 24, 2024, or six months before the expiration of Allergan's patents, points to the complexity of Restasis and the difficulty of getting a generic version approved, Maris tells investors in a research note. InnoPharma was one of four included in a consolidated lawsuit against Allergan, with Teva (TEVA), Mylan (MYL) and Akorn (AKRX) remaining, Maris points out. He's encouraged that the settlement date reached with InnoPharma is close to the expiration date of the patents. The analyst keeps an Outperform rating on Allergan with a $276 price target.
GILD Gilead
$80.10

-0.07 (-0.09%)

10/11/17
LEHM
10/11/17
INITIATION
Target $90
LEHM
Overweight
Gilead reinstated with an Overweight at Barclays
Barclays analyst Geoff Meacham reinstated Gilead Sciences with an Overweight rating and $90 price target. The company will continue to attract investor attention as its expansion into oncology puts visibility into the resumption of growth, the analyst contends.
10/19/17
MSCO
10/19/17
NO CHANGE
MSCO
Equal Weight
Gilead faces patent battle with Juno over Yescarta, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Juno (JUNO) has filed a lawsuit in the Central District of California alleging that Gilead's (GILD) newly-approved Yescarta infringes a patent that is exclusively licensed to Juno from Memorial Sloan Kettering. The analyst, who said he would expect a modest royalty to Juno, sees this fight as a source of potential upside to Juno but not as a major headwind for Gilead. Harrison, who said in a separate note to investors that Yescarta's pricing and timeline appear in-line with expectations, keeps Equal Weight ratings on both Gilead and Juno.
10/19/17
WBLR
10/19/17
NO CHANGE
WBLR
Outperform
Gilead CAR-T priced below expectations, says William Blair
William Blair analyst Y. Katherine Xu says the $373,000 price for Gilead Sciences' CAR-T product Yescarta is below her estimate of $425,000. The analyst lowered her peak sales estimate for Yescarta to $3.3B from $4.1B but notes the change does not materially affect her fair value estimate of Gilead shares, which she keeps at $87. Xu keeps an Outperform rating on Gilead.
10/19/17
JEFF
10/19/17
NO CHANGE
JEFF
Hold
Gilead CAR-T approval comes early, pricing in-line, says Jefferies
Jefferies analyst Michael Yee says approval of Gilead Sciences' CAR-T Yescarta came one month ahead of expectations and the list price of $373,000 is in-line with expectations. The analyst expects the launch to be strong over the course of the year and estimates 2018 revenue above consensus in the $200M-$250M range. Yee keeps a Hold rating on Gilead, saying hepatitis C virus numbers remain too high and need to come down.
ALXN Alexion
$136.66

1.46 (1.08%)

10/24/17
RBCM
10/24/17
NO CHANGE
Target $166
RBCM
Outperform
Alexion price target raised to $166 from $161 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Alexion to $166 after yesterday's Soliris FDA approval. MacKay reiterates that the broad label could lead to Soliris usage in up to 20-25% of myasthenia gravis patients, representing "significant upside" to the 10-15% of patients that are considered "refractory".
10/24/17
LEER
10/24/17
NO CHANGE
Target $178
LEER
Outperform
Alexion Soliris sBLA approval in gMG resolves uncertainty, says Leerink
Leerink analyst Geoffrey Porges notes that Alexion announced that the FDA approved its supplemental biologics license application for Soliris in the treatment of refractory generalized myasthenia gravis, or gMG, patients who are antiacetylcholine receptor antibody positive. The announcement and label should be well received by investors, and lift some recent downside risk and allow investors to look ahead to potential positive catalysts for ALXN1210 in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, and Soliris in neuromyelitis optica, next year. Porges reiterates an Outperform rating and $178 price target on the shares.
10/24/17
PIPR
10/24/17
NO CHANGE
Target $32
PIPR
Overweight
Argenx drug has differentiated mechanism to treat MG, says Piper Jaffray
After news that the FDA approved an expanded label for Alexion's (ALXN) Soliris to treat generalized Myasthenia Gravis, or gMG, Piper Jaffray analyst Edward Tenthoff said that while this is a significant milestone he still sees room for new therapies. He believes that Argenx's (ARGX) ARGX-113 has a differentiated mechanism to treat MG and notes it is scheduled to report Phase 2 data on the drug in that indication in the first quarter of 2018. Tenthoff reiterates his Overweight rating and $32 price target on Argenx shares, which are down nearly 4% to $19.42 in morning trading.
10/24/17
COWN
10/24/17
NO CHANGE
Target $180
COWN
Outperform
Soliris approval gives Alexion another $1B-plus opportunity, says Cowen
Cowen analyst Eric Schmidt noted Alexion received FDA approval for Soliris for the treatment of adults with generalized myasthenia gravis. The analyst noted this is the drug's third indication and represents another $1B-plus opportunity. Schmidt called Alexion a top large cap pick and reiterated his Outperform rating and $180 price target on the shares.
GSK GlaxoSmithKline
$40.48

-0.14 (-0.34%)

08/30/17
ARGS
08/30/17
NO CHANGE
ARGS
GlaxoSmithKline weakness creates buying opportunity, says Argus
Argus analyst John Eade says that the 8% decline in GlaxoSmithKline's stock over the past quarter has created a buying opportunity. The analyst expects the company's profits to rise by low single percentage digits in 2017 and 2018, and he calls its 5% dividend yield attractive.
07/10/17
PIPR
07/10/17
NO CHANGE
Target $5
PIPR
Neutral
OncoMed termination from GSK not surprising, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes GlaxoSmithKline (GSK) terminating its agreement with OncoMed Pharmaceuticals (OMED) is not surprising since tarextumab, the only remaining asset under the collaboration, failed previously to meet the primary endpoint in a Phase II study for first-line small cell lung cancer. The analyst says he remains focused on OncoMed's early stage pipeline including navicixizumab, rosmantuzumab and I/O assets anti-TIGIT and GITR trimer. Tenthoff keeps a Neutral rating on OncoMed with a $5 price target.
09/08/17
MSCO
09/08/17
DOWNGRADE
MSCO
Underweight
GlaxoSmithKline downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Vincent Meunier downgraded GlaxoSmithKline to Underweight saying its 2020 roadmap appears "challenging" given capital allocation constraints and low R&D optionality.
REGN Regeneron
$426.51

-6.25 (-1.44%)

10/20/17
LEHM
10/20/17
UPGRADE
Target $70
LEHM
Overweight
Seattle Genetics upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Seattle Genetics to Overweight and raised his price target for the shares to $70 from $60. The biotechnology company closed yesterday up 33c to $64.01. The analyst has increased conviction in the company's Echelon-1 study, which is evaluating Adectris as part of a frontline combination chemotherapy regimen in 1,334 patients with previously untreated advanced classical Hodgkin lymphoma. Due diligence indicates clinicians are largely willing to accept a marginal gain in efficacy for a meaningful improvement in safety/toxicity, Meacham tells investors in a research note. The analyst now models peak Adcetris U.S. classical Hodgkin lymphoma sales at $1.2B, versus a prior $900M, with peak sales across all indications at $1.8B, above the consensus of $1.5B. Meacham this morning also downgraded Regeneron Pharmaceuticals (REGN) to Underweight from Equal Weight.
10/20/17
LEHM
10/20/17
DOWNGRADE
Target $395
LEHM
Underweight
Regeneron downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham downgraded Regeneron Pharmaceuticals to Underweight and cut his price target for the shares to $395 from $450. Following a physician survey, the analyst believes expectations for Dupixent in atopic dermatitis and asthma are too high. Despite positive views by physicians, treatment rates in moderate-to-severe atopic dermatitis populations "remain modest" and are not expected to grow to support Street expectations, Meacham tells investors in a research note. He adds that asthma will also likely be a competitive market.
10/23/17
GUGG
10/23/17
INITIATION
Target $540
GUGG
Buy
Regeneron initiated with a Buy at Guggenheim
Guggenheim analyst Adnan Butt initiated Regeneron with a Buy and $540 price target.
10/20/17
10/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PulteGroup (PHM) downgraded to Sell from Neutral at Citi with analyst Will Randow saying the 49% year-to-date share rally has been exaggerated by the company's $1B share repurchase program that likely will sunset at year-end. 2. Celgene (CELG) was downgraded to Neutral from Buy at Citi and to Neutral from Outperform at Baird. 3. HP Enterprise (HPE) downgraded to Neutral from Buy at UBS with analyst Steven Milunovich saying the company's streamlining plans make sense but could prove disruptive and its pivot to higher margin revenue will take time. 4. Regeneron (REGN) downgraded to Underweight from Equal Weight at Barclays with analyst Geoff Meacham saying he believes expectations for Dupixent in atopic dermatitis and asthma are too high. 5. Bojangles (BOJA) downgraded to Market Perform from Outperform at Cowen with analyst Andrew Charles saying his survey data leaves him concerned whether the company can successfully implement value efforts to drive traffic amid intensified industry focus on value, which is likely to persist through 2018. Charles lowered his price target to $14 from $20 on Bojangles shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CELG Celgene
$120.34

-2.03 (-1.66%)

10/23/17
GUGG
10/23/17
INITIATION
Target $160
GUGG
Buy
Celgene initiated with a Buy at Guggenheim
Guggenheim analyst Adnan Butt initiated Celgene with a Buy rating and $160 price target.
10/23/17
10/23/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Electric (GE) was downgraded to Neutral from Buy at UBS and to Underweight from Equal Weight at Morgan Stanley. 2. SunTrust (STI) was downgraded to Hold from Buy at Sandler O'Neill and to Market Perform from Outperform at Raymond James. 3. Celgene (CELG) assumed with a Neutral from Overweight at Piper Jaffray with analyst Christopher Raymond saying that after Friday's failure of GED-301, investors are now "far less likely to assign the benefit of doubt to other pipeline investments." 4. Buckingham downgraded Foot Locker (FL) to Neutral from Buy and slashed its price target to $29 from $47 telling investor's major catalysts are several quarters away and risk/reward is mostly balanced. 5. Biogen (BIIB) downgraded to Neutral from Buy at Citi with analyst Robyn Karnauskas saying her Spinraza thesis has largely played out while spinal muscular atrophy competition and multiple sclerosis pricing moves her to the sidelines. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/23/17
LEER
10/23/17
NO CHANGE
Target $156
LEER
Outperform
Revlimid trials a potentially 'significant' catalyst for Celgene, says Leerink
Leerink analyst Geoffrey Porges says that ongoing phase III trials for Revlimid in non-Hodgkin lymphoma are a potentially "significant" catalyst for Celgene investors late in 2017 or early in 2018. The analyst believes that these indications could boost consensus revenue expectations for Revlimid by up to $1B in 2022, and at the stock's current multiples of revenue and earnings, this would be worth as much as $7-$8/share in upside. He reiterates an Outperform and $156 price target on the shares.
10/23/17
PIPR
10/23/17
DOWNGRADE
Target $133
PIPR
Neutral
Celgene assumed with a Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded Celgene to Neutral after assuming coverage of the name. Following Friday's failure of GED-301, investors are now "far less likely to assign the benefit of doubt to other pipeline investments," Raymond tells investors in a research note. He lowered his price target for the shares to $133 from $145.
LLY Eli Lilly
$85.17

-2.01 (-2.31%)

10/10/17
10/10/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. HSBC (HSBC) downgraded to Underperform from Neutral at Credit Suisse with analyst Sanjay Jain citing valuation. 2. Jabil Circuit (JBL) downgraded to Sell from Neutral at Goldman Sachs with analyst Mark Delaney saying street expectations, which assume Jabil's earnings grow double digits year-over-year for both of the next two years, are overly optimistic. 3. Carlyle Group (CG) downgraded to Neutral from Buy at Citi with analyst William Katz citing valuation with the shares up 60% year-to-date. 4. Eli Lilly (LLY) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan saying the valuation looks full with the shares up 13% since mid-August. 5. Ralph Lauren (RL) downgraded to Sell from Hold at Miller Tabak. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AMGN Amgen
$180.37

-0.16 (-0.09%)

10/05/17
BOFA
10/05/17
NO CHANGE
BOFA
Buy
Amgen price target raised to $210 at BofA/Merrill
BofA/Merrill analyst Ying Huang raised Amgen's price target to $210 to reflect the potential impact of proposed tax reform and benefits from a potential repatriation of profits. Huang rates Amgen a Buy.
10/04/17
WEDB
10/04/17
NO CHANGE
Target $37
WEDB
Outperform
CytomX Therapeutics price target raised to $37 from $26 at Wedbush
Wedbush analyst Robert Driscoll raised his price target for CytomX Therapeutics (CTMX) to $37 from $26 to reflect his increased confidence in its platform, and the extended cash runway, which the company believes to be sufficient to at least 2020. The analyst notes that the company has added Amgen (AMGN) to the Partner List with Bispecific Collaboration. He reiterates an Outperform rating on CytomX Therapeutics' shares.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$315.05

2.55 (0.82%)

10:21
11/18/17
11/18
10:21
11/18/17
10:21
Periodicals
Tesla new super car to cost $200,000, Recode says »

Alongside its new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 16

    Jan

GT

Goodyear Tire

$29.94

0.63 (2.15%)

10:17
11/18/17
11/18
10:17
11/18/17
10:17
Hot Stocks
Goodyear Tire, NASCAR extend relationship »

NASCAR and Goodyear Tire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Jan

  • 16

    Jan

HMC

Honda

$32.62

0.02 (0.06%)

10:05
11/18/17
11/18
10:05
11/18/17
10:05
Periodicals
Honda recalls 900,000 minivans on tip forward seats, Reuters says »

Honda Motor is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$88.43

-0.82 (-0.92%)

09:48
11/18/17
11/18
09:48
11/18/17
09:48
Periodicals
Activist investors Nelson Peltz still in P&G picture, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

, GE

General Electric

$18.21

-0.04 (-0.22%)

09:39
11/18/17
11/18
09:39
11/18/17
09:39
Periodicals
Buy Baker Hughes, Barron's says »

While it is "not…

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

GE

General Electric

$18.21

-0.04 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

CSCO

Cisco

$35.90

0.02 (0.06%)

09:19
11/18/17
11/18
09:19
11/18/17
09:19
Periodicals
More needed for Cisco to have 'groove back,' Barron's says »

While the Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

IBM

IBM

$148.97

-0.15 (-0.10%)

09:10
11/18/17
11/18
09:10
11/18/17
09:10
Periodicals
IBM could be next to fetch higher valuation, Barron's says »

Investors are warming to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

GE

General Electric

$18.21

-0.04 (-0.22%)

09:05
11/18/17
11/18
09:05
11/18/17
09:05
Periodicals
Option play offer some help given GE dividend, depressed stock, Barron's says »

While wagering against…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

09:00
11/18/17
11/18
09:00
11/18/17
09:00
Periodicals
Risk remains after GE dividend cut, Barron's says »

While buying General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$88.72

0.71 (0.81%)

, T

AT&T

$34.51

-0.01 (-0.03%)

08:21
11/18/17
11/18
08:21
11/18/17
08:21
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

TWX

Time Warner

$88.72

0.71 (0.81%)

T

AT&T

$34.51

-0.01 (-0.03%)

NYT

New York Times

$17.65

0.05 (0.28%)

TEX

Terex

$44.82

0.8 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

TPIC

TPI Composites

$19.06

-0.97 (-4.84%)

07:25
11/18/17
11/18
07:25
11/18/17
07:25
Conference/Events
TPI Composites to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SYNA

Synaptics

$38.21

0.57 (1.51%)

04:55
11/18/17
11/18
04:55
11/18/17
04:55
Conference/Events
Synaptics management to meet with KeyBanc »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 06

    Dec

WGL

WGL Holdings

$84.32

-0.14 (-0.17%)

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Earnings
WGL Holdings reports Q4 adjusted EPS (17c), consensus (19c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

, LMOS

Lumos Networks

17:58
11/17/17
11/17
17:58
11/17/17
17:58
Hot Stocks
Tactile Systems to replace Lumos Networks in S&P 600 at open on 11/22 »

EQT Infrastructure…

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

, MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

17:56
11/17/17
11/17
17:56
11/17/17
17:56
Hot Stocks
Breaking Hot Stocks news story on Invesco Mortgage, MKS Instruments »

Invesco Mortgage to…

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

17:55
11/17/17
11/17
17:55
11/17/17
17:55
Hot Stocks
MKS Instruments to replace Brocade in S&P 400 at open on 11/22 »

S&P 500 constituent…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

UQM

UQM Technologies

$1.18

0.015 (1.29%)

17:24
11/17/17
11/17
17:24
11/17/17
17:24
Syndicate
Breaking Syndicate news story on UQM Technologies »

UQM Technologies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$238.02

-1.35 (-0.56%)

17:23
11/17/17
11/17
17:23
11/17/17
17:23
Periodicals
Goldman Sachs has $510M lawsuit dismissed, Reuters reports »

A $510M lawsuit that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.94

-0.02 (-1.02%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Breaking Hot Stocks news story on Vical »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Ligand director sells 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CFO sells 6,559 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CEO sells 5,269 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBI

MBIA

$9.01

0.13 (1.46%)

17:15
11/17/17
11/17
17:15
11/17/17
17:15
Hot Stocks
Breaking Hot Stocks news story on MBIA »

Fine Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBCN

Rubicon

$8.07

0.1218 (1.53%)

17:03
11/17/17
11/17
17:03
11/17/17
17:03
Hot Stocks
Breaking Hot Stocks news story on Rubicon »

Bandera Partners reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.